Total submissions: 5
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Labcorp Genetics |
RCV000538799 | SCV000658672 | likely benign | LAMA2-related muscular dystrophy | 2025-01-31 | criteria provided, single submitter | clinical testing | |
| Mayo Clinic Laboratories, |
RCV001508558 | SCV001714785 | uncertain significance | not provided | 2021-04-05 | criteria provided, single submitter | clinical testing | |
| Revvity Omics, |
RCV001508558 | SCV003814041 | uncertain significance | not provided | 2020-08-20 | criteria provided, single submitter | clinical testing | |
| Athena Diagnostics | RCV001508558 | SCV004229762 | uncertain significance | not provided | 2022-12-05 | criteria provided, single submitter | clinical testing | Available data are insufficient to determine the clinical significance of the variant at this time. The frequency of this variant in the general population is uninformative in assessment of its pathogenicity (http://gnomad.broadinstitute.org). Computational tools predict that this variant is not damaging. |
| Ambry Genetics | RCV004024401 | SCV004895577 | uncertain significance | Inborn genetic diseases | 2023-10-02 | criteria provided, single submitter | clinical testing | The c.3628A>G (p.I1210V) alteration is located in exon 25 (coding exon 25) of the LAMA2 gene. This alteration results from a A to G substitution at nucleotide position 3628, causing the isoleucine (I) at amino acid position 1210 to be replaced by a valine (V). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |